121 related articles for article (PubMed ID: 37031549)
21. A 20-year incidence trend (1989-2008) and point prevalence (March 20, 2009) of multiple sclerosis in Tehran, Iran: a population-based study.
Elhami SR; Mohammad K; Sahraian MA; Eftekhar H
Neuroepidemiology; 2011; 36(3):141-7. PubMed ID: 21508646
[TBL] [Abstract][Full Text] [Related]
22. Comorbidities at multiple sclerosis diagnosis.
Fromont A; Binquet C; Rollot F; Despalins R; Weill A; Clerc L; Bonithon-Kopp C; Moreau T
J Neurol; 2013 Oct; 260(10):2629-37. PubMed ID: 23907437
[TBL] [Abstract][Full Text] [Related]
23. Comorbidity, socioeconomic status and multiple sclerosis.
Marrie R; Horwitz R; Cutter G; Tyry T; Campagnolo D; Vollmer T
Mult Scler; 2008 Sep; 14(8):1091-8. PubMed ID: 18728060
[TBL] [Abstract][Full Text] [Related]
24. Modification of claims-based measures improves identification of comorbidities in non-elderly women undergoing mastectomy for breast cancer: a retrospective cohort study.
Nickel KB; Wallace AE; Warren DK; Ball KE; Mines D; Fraser VJ; Olsen MA
BMC Health Serv Res; 2016 Aug; 16(a):388. PubMed ID: 27527888
[TBL] [Abstract][Full Text] [Related]
25. Epidemiology of multimorbidity in Iran: An investigation of a large pharmacy claims database.
Ebrahimoghli R; Janati A; Sadeghi-Bazargani H; Hamishehkar H; Ghaffari S; Sanaat Z; Farahbakhsh M; Farhoudi M; Khalili-Azimi A
Pharmacoepidemiol Drug Saf; 2020 Jan; 29(1):39-47. PubMed ID: 31730260
[TBL] [Abstract][Full Text] [Related]
26. Feasibility of Using a Nationally Representative Telephone Survey to Monitor Multiple Sclerosis Prevalence in the United States.
Buka SL; Wallin MT; Culpepper WJ; Lee YH; Marrie RA; Nelson LM; Kaye WE; Wagner L; Tremlett H; Campbell J; LaRocca N
Neuroepidemiology; 2020; 54(2):123-130. PubMed ID: 31991409
[TBL] [Abstract][Full Text] [Related]
27. Comorbidity in lung cancer patients and its association with hospital readmission and fatality in China.
Zhu D; Ding R; Ma Y; Chen Z; Shi X; He P
BMC Cancer; 2021 May; 21(1):557. PubMed ID: 34001011
[TBL] [Abstract][Full Text] [Related]
28. Patterns of Comorbidity and Multimorbidity Among Patients With Multiple Sclerosis in a Large US Commercially Insured and Medicare Advantage Population.
Dai D; Sharma A; Phillips AL; Lobo C
J Health Econ Outcomes Res; 2022; 9(2):125-133. PubMed ID: 36475279
[No Abstract] [Full Text] [Related]
29. Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis.
Zhang T; Tremlett H; Leung S; Zhu F; Kingwell E; Fisk JD; Bhan V; Campbell TL; Stadnyk K; Yu BN; Marrie RA;
Neurology; 2016 Apr; 86(14):1287-1295. PubMed ID: 26944268
[TBL] [Abstract][Full Text] [Related]
30. Sex differences in comorbidity at diagnosis of multiple sclerosis: A population-based study.
Marrie RA; Patten SB; Tremlett H; Wolfson C; Warren S; Svenson LW; Jette N; Fisk J;
Neurology; 2016 Apr; 86(14):1279-1286. PubMed ID: 26962066
[TBL] [Abstract][Full Text] [Related]
31. Management of diabetes and hypertension in people with multiple sclerosis.
Marrie RA; Kosowan L; Singer A
Mult Scler Relat Disord; 2020 May; 40():101987. PubMed ID: 32062442
[TBL] [Abstract][Full Text] [Related]
32. Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: An observational study using the US Department of Defense administrative claims database.
Capkun G; Dahlke F; Lahoz R; Nordstrom B; Tilson HH; Cutter G; Bischof D; Moore A; Simeone J; Fraeman K; Bancken F; Geissbühler Y; Wagner M; Cohan S
Mult Scler Relat Disord; 2015 Nov; 4(6):546-54. PubMed ID: 26590661
[TBL] [Abstract][Full Text] [Related]
33. Incidence and prevalence of multiple sclerosis in southeastern Iran.
Moghtaderi A; Rakhshanizadeh F; Shahraki-Ibrahimi S
Clin Neurol Neurosurg; 2013 Mar; 115(3):304-8. PubMed ID: 22717599
[TBL] [Abstract][Full Text] [Related]
34. Estimating annual prevalence of depression and anxiety disorder in multiple sclerosis using administrative data.
Marrie RA; Walld R; Bolton JM; Sareen J; Walker JR; Patten SB; Singer A; Lix LM; Hitchon CA; El-Gabalawy R; Katz A; Fisk JD; Bernstein CN;
BMC Res Notes; 2017 Nov; 10(1):619. PubMed ID: 29178935
[TBL] [Abstract][Full Text] [Related]
35. Influence of hypertension, diabetes, hyperlipidemia, and obstructive lung disease on multiple sclerosis disease course.
Conway DS; Thompson NR; Cohen JA
Mult Scler; 2017 Feb; 23(2):277-285. PubMed ID: 27230791
[TBL] [Abstract][Full Text] [Related]
36. Determining the cost of obesity and its common comorbidities from a commercial claims database.
Padula WV; Allen RR; Nair KV
Clin Obes; 2014 Feb; 4(1):53-8. PubMed ID: 25425133
[TBL] [Abstract][Full Text] [Related]
37. Comorbidity in US patients with multiple sclerosis.
Edwards NC; Munsell M; Menzin J; Phillips AL
Patient Relat Outcome Meas; 2018; 9():97-102. PubMed ID: 29491723
[TBL] [Abstract][Full Text] [Related]
38. Performance of administrative case definitions for comorbidity in multiple sclerosis in Manitoba and Nova Scotia.
Marrie RA; Fisk JD; Stadnyk KJ; Tremlett H; Wolfson C; Warren S; Bhan V; Yu BN;
Chronic Dis Inj Can; 2014 Jul; 34(2-3):145-53. PubMed ID: 24991777
[TBL] [Abstract][Full Text] [Related]
39. Evidence of an increased prevalence of multiple sclerosis: a population-based study of Tehran registry during 1999-2018.
Almasi-Hashiani A; Sahraian MA; Eskandarieh S
BMC Neurol; 2020 May; 20(1):169. PubMed ID: 32359352
[TBL] [Abstract][Full Text] [Related]
40. The use of disease-modifying new drugs for multiple sclerosis treatment in private-sector health plans.
Ozminkowski RJ; Marder WD; Hawkins K; Wang S; Stallings SC; Finkelstein SN; Sinskey AJ; Wierz D
Clin Ther; 2004 Aug; 26(8):1341-54. PubMed ID: 15476915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
